… In conclusion, preoperative exposure to vedolizumab in IBD patients undergoing abdominal
surgery does not appear to significantly increase the risk of postoperative infectious and …

… have been evaluated from four double-blind and two open-label trials in an analysis that
included over 2800 vedolizumab-exposed patients with IBD who were treated for up to 5 years[…

… The majority of patients reported in this study had been exposed to several biological agents…
exposed to anti-TNF agents. We could not evaluate the correlation between vedolizumab …

… Disease severity, particularly at conception, strongly influences the IBD course during …
Vedolizumab (VDZ) treatment is approved for ulcerative colitis and Crohn's disease (CD), based …

… The current total number of PY of vedolizumab exposure was estimated as specified above
(in the Patients and Data Collection section), and the likely future exposure to vedolizumab …

… database, incidence rates of Crohn’s disease (CD) and ulcerative colitis (UC) were …
low sunlight exposure is associated with an increased incidence of Crohn's disease. Further …

… and placental insufficiency with in utero growth restriction; no increased risk of these outcomes
was observed after vedolizumab exposure in this study or in any other cohorts. 19, 20, 21 …

… ’s disease and ulcerative colitis in the pivotal GEMINI trials. In … as patients with isolated
small bowel disease inaccessible to … , perianal disease, and previous anti-TNF exposure were …

… of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. …
Patients with prior anti-TNF exposure were more likely to experience new or worsening …

… Current models are able to predict that those patients with less severe disease, without
prior biologic exposure and who demonstrate early response to VDZ have the highest rates of …